{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-179834","form_type":"8-K","ticker":"ACRV","cik":"0001781174","company_name":"Acrivon Therapeutics, Inc.","filed_at":"2025-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.968462+00:00","generated_at":"2026-05-17T13:58:13.293386+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Acrivon Q2 net loss $21.0M, cash $147.6M; advances ACR-368 and ACR-2316 trials","bullets":["Net loss of $21.0M for Q2 2025, up from $18.8M in Q2 2024; R&D spend $16.2M.","Cash, equivalents and investments of $147.6M as of June 30, 2025; expected runway into Q2 2027.","Initiated Phase 2b third arm for ACR-368 with ultra low-dose gemcitabine in biomarker-unselected endometrial cancer.","ACR-2316 Phase 1 dose escalation shows initial clinical activity, including confirmed partial response in endometrial cancer.","Anticipated H2 2025 milestones: update on registrational ACR-368 trial and initial Phase 1 data for ACR-2316."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-179834","json":"https://secwatch.observer/filing/0001193125-25-179834.json","markdown":"https://secwatch.observer/filing/0001193125-25-179834.md","text":"https://secwatch.observer/filing/0001193125-25-179834.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1781174/000119312525179834/0001193125-25-179834-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1781174/000119312525179834/acrv-20250813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:58:13.293386+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}